Myriad Genetics is a leading molecular diagnostic company dedicated to saving lives and improving the quality of life for patients through the discovery and commercialization of novel, transformative diagnostic tests for several major diseases, including cancer, rheumatoid arthritis, diabetes and more. We are changing the way patients, healthcare professionals and researchers view disease by providing molecular diagnostic and companion diagnostic tests that can be used to:
Since discovering the BRCA1 gene associated with hereditary breast and ovarian cancer (HBOC) in 1994 and launching our first hereditary cancer genetic test, BRACAnalysis® in 1996, Myriad has been a pioneer in molecular diagnostics. The Company has been and continues to be a trailblazer in personalized medicine, expanding our products to include molecular and companion diagnostic tests for use in the fields of oncology, preventive care, urology, dermatology, neuroscience and autoimmune diseases.
Myriad’s tests are currently being used to improve the understanding and treatment of: